OncoMatch/Clinical Trials/NCT06768489
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma
Is NCT06768489 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including JNJ-79635322 and Daratumumab for multiple myeloma.
Treatment: JNJ-79635322 · Daratumumab · Pomalidomide · Lenalidomide — The primary purpose of this study for Part 1 (Dose Escalation) is to identify the safe effective dose (recommended Phase 2 doses \[RP2Ds\]) and schedule for JNJ-79635322 treatment regimen in combination with daratumumab with or without lenalidomide or with pomalidomide; and for Part 2 (Dose Expansion) is to further characterize the safety and tolerability of JNJ-79635322 combination treatment regimens at selected RP2D(s).
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: targeted therapy
Targeted therapy ... within 21 days or 5 half-lives, whichever is less
Cannot have received: epigenetic therapy
epigenetic therapy ... within 21 days or 5 half-lives, whichever is less
Cannot have received: monoclonal antibody
monoclonal antibody (mAb) treatment ... within 21 days or 5 half-lives, whichever is less
Cannot have received: investigational drug
treatment with an investigational drug or an invasive investigational medical device within 21 days or 5 half-lives, whichever is less
Cannot have received: gene-modified adoptive cell therapy
Gene-modified adoptive cell therapy (example, chimeric antigen receptor [CAR] modified T cells, natural killer cells) within 90 days
Cannot have received: anti-CD38 directed therapy
Exception: for treatment regimen A only: within 90 days; for regimen B: within 21 days
Prior anti-CD38 directed therapy within 90 days (for treatment regimen A only; within 21 days for treatment regimen B)
Cannot have received: conventional chemotherapy
Conventional chemotherapy within 21 days
Cannot have received: proteasome inhibitor
PI therapy within 14 days
Cannot have received: immunomodulatory agent
Immunomodulatory agent therapy within 7 days
Cannot have received: radiation therapy
Radiotherapy within 14 days
Cannot have received: allogeneic stem cell transplant
Allogeneic stem cell transplant within 6 months before the first dose of study treatment
Cannot have received: autologous stem cell transplant
Exception: received less than or equal to (<=)12 weeks before the first dose of study treatment
Received an autologous stem cell transplant less than or equal to (<=)12 weeks before the first dose of study treatment
Cannot have received: CD3-redirecting therapy
Prior treatment with CD3-redirecting therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify